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Abstract
Background: Mutation detection in clinical tumour samples is challenging when the proportion of
tumour cells, and thus mutant alleles, is low. The limited sensitivity of conventional sequencing
necessitates the adoption of more sensitive approaches. High resolution melting (HRM) is more
sensitive than sequencing but identification of the mutation is desirable, particularly when it is
important to discriminate false positives due to PCR errors or template degradation from true
mutations.
We thus developed limited copy number - high resolution melting (LCN-HRM) which applies
limiting dilution to HRM. Multiple replicate reactions with a limited number of target sequences per
reaction allow low level mutations to be detected. The dilutions used (based on Ct values) are
chosen such that mutations, if present, can be detected by the direct sequencing of amplicons with
aberrant melting patterns.
Results: Using cell lines heterozygous for mutations, we found that the mutations were not readily
detected when they comprised 10% of total alleles (20% tumour cells) by sequencing, whereas they
were readily detectable at 5% total alleles by standard HRM. LCN-HRM allowed these mutations
to be identified by direct sequencing of those positive reactions.
LCN-HRM was then used to review formalin-fixed paraffin-embedded (FFPE) clinical samples
showing discordant findings between sequencing and HRM for KRAS exon 2 and EGFR exons 19 and
21. Both true mutations present at low levels and sequence changes due to artefacts were detected
by LCN-HRM. The use of high fidelity polymerases showed that the majority of the artefacts were
derived from the damaged template rather than replication errors during amplification.
Conclusion: LCN-HRM bridges the sensitivity gap between HRM and sequencing and is effective
in distinguishing between artefacts and true mutations.
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Background
The recent demonstrations of the clinical benefits of
molecularly targeted therapies [1,2] have greatly increased
the demand for cost-effective and reliable methods of
mutation detection in individual tumour samples. How-
ever, clinical tumour samples are typically heterogeneous,
containing a mixture of cancer cells and various normal
cell types. The proportion of cancer cells can be quite low
and often limited amounts of material are available for
analysis. The cancer cells may also show clonal heteroge-
neity, and thus a particular genetic change may not be
present in all of the tumour cells [3]. All of these factors
present challenges for mutation detection in clinical sam-
ples.
Dideoxynucleotide sequencing is often considered the
gold standard for detection of genetic changes as it allows
these changes to be directly characterised. However, to be
reliably detected, changes are required to be present at a
proportion of at least 10-20% at the allelic level [4]. Thus,
lower levels of mutations, due to high contamination
with normal cells or tumour heterogeneity, can not be
detected by sequencing when the mutations are present
below the sensitivity of sequencing.
Various PCR-based techniques for detecting sequence var-
iation have been reported, demonstrating both advan-
tages and disadvantages in terms of sensitivity, simplicity,
cost-efficiency and robustness. This article will focus on
the detection of EGFR and KRAS mutations, although the
principles can be extended to mutations in any gene.
Reported techniques available for detection of mutations
in these genes include; dideoxynucleotide sequencing,
single strand conformation analysis [5], TaqMan PCR [6],
amplification refractory mutation system monitored by
Scorpion probes [7], denaturing high pressure liquid
chromatography [8], pyrosequencing [9], massively paral-
lel sequencing [10,11], cold-PCR [12], mutant-enriched
PCR [13] and high resolution melting [14,15].
High resolution melting (HRM) is an in-tube scanning
methodology that detects sequence variation by monitor-
ing the melting behaviour of PCR amplicons using DNA
intercalating fluorescent dyes. HRM has been used for a
variety of genetic and epigenetic studies [14-18]. It has
been demonstrated to be more sensitive than dideoxynu-
cleotide sequencing for the detection of somatic muta-
tions [19]. In our previous study, KRAS mutations were
able to be detected at levels as low as 5% by HRM [14].
Like other scanning methods, HRM results often need to
be confirmed and characterised by a sequencing method-
ology. Dideoxynucleotide sequencing is the most com-
monly used methodology. Discordant results between
sequencing and HRM may be anticipated if the mutant
alleles are present at 5 to 20% due to the different sensi-
tivity of the two methods.
In this study, we report a new method, LCN-HRM, for
detection and subsequent identification by sequencing of
low levels of sequence variation, particularly those that
are only detectable by HRM. The basic principle of this
methodology is that low level mutant alleles which can-
not be detected in the presence of large amounts of nor-
mal alleles are present at higher proportions when the
sample is diluted at low copy numbers in multiple aliq-
uots (limiting dilution) [20,21]. The range of copy num-
bers are chosen so that aliquots containing mutations can
be detected with HRM and the mutations can then be
characterised by direct sequencing of the aberrant ampli-
cons.
Methods
Samples and DNA extraction
This study was covered by an approval from the Peter
MacCallum Cancer Centre Ethics Committee (project
number 03/90). Two cancer cell lines, HCT116 and NCI-
H1650, were used. HCT116 contains a KRAS exon 2 mis-
sense mutation whereas NCI-H1650 harbours a EGFR
exon 19 deletion mutation. Peripheral blood from four
normal individuals was used as a source of DNA for the
quantitative estimation of target copy number and as nor-
mal DNA for the cell line dilution experiments. Genomic
DNA was extracted from the cell lines and peripheral
blood using the QIAamp DNA blood kit (Qiagen, Hilden,
Germany) according to the manufacturer's instructions.
DNA was quantified with a NanoDrop ND-1000 Fluor-
ospectrometer (NanoDrop, Wilmington, DE). Four for-
malin-fixed paraffin-embedded (FFPE) DNA samples
from non-small cell lung cancer (NSCLC) patients were
included to investigate the cause of previously reported
discrepancies between HRM and sequencing results [15].
PCR and HRM conditions
Real time PCR amplification and HRM were performed
on the Rotor-Gene Q (Qiagen, Hilden, Germany). The
HRM primers for KRAS exon 2 [14] and EGFR exon 19
[15] generated 189 bp and 250 bp products respectively.
The conditions for KRAS exon 2 were as follows. The reac-
tion mixture (20 μl final volume) contained the template,
1× PCR buffer, 2.5 mM MgCl2, 200 nM each primer, 200
μM dNTPs, 5 μM SYTO 9 (Invitrogen, Carlsbad, CA) and
0.5 U HotStarTaq (Qiagen). The cycling and melting con-
ditions were; one cycle of 95°C for 15 minutes; 55 cycles
of 95°C for 10 seconds, 67.5°C for 5 seconds with an ini-
tial 10 cycles of touchdown from 67.5°C to 57.5°C (1°C/
cycle), 72°C for 20 seconds; one cycle of 97°C for one
minute and a melt from 70°C to 95°C rising 0.2°C per
second. For LCN-HRM, the conditions were the same
except that 60 cycles of amplification were used. TheMolecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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cycling conditions for the EGFR exon 19 assay were iden-
tical except that the initial annealing temperature was
65°C. The melting profiles of amplicons were analysed
using the Rotor-Gene Software (v1.7).
Preparation of standard dilutions using quantitative real-
time PCR (qPCR)
The amount of amplifiable template for each DNA sample
is most accurately estimated by qPCR, particularly when
an accurate dilution series is required. For high quality
DNA, any amplicon should yield similar results. We used
previously reported KRAS primers which generated a 189
bp product [14] and EGFR primers which generated a 250
bp product [14]. PCR conditions were as above. The cycle
threshold (Ct) value was determined by setting the thresh-
old at 0.1 in the quantitation analysis of the Rotor-Gene
software. Using the qPCR data, a range of cell line DNA
dilutions from 20% to 1% mutant allele frequency was
prepared.
qPCR for copy number estimation prior to limiting dilution
When dealing with FFPE specimens, the degree of frag-
mentation will affect the amount of template molecules
that can be amplified. The effective copy number of
amplifiable template for each DNA sample is again most
accurately estimated by qPCR. In high quality DNA, there
is an average of one copy of an autosomal gene per 3 pg
of DNA. The effective copy number in the sample is
obtained by comparing the Ct of the sample with the Ct
value of a high quality reference. To correct for the varia-
ble amounts of DNA fragmentation, the amplicon used
for the estimation needs to be in the same size range as the
amplicons being screened for mutations. It is ideal to use
the same amplicon that is being screened.
The qPCR data was used for calculation of the dilution
factor which gave approximately four copies of template
(12 pg) per reaction. To estimate the necessary dilution,
the Ct value of the sample (Cts) was compared to the Ct
value of reference DNA (Ctref) of a known concentration.
The comparative quantitation analysis of the Rotor-Gene
software was used to calculate the PCR efficiency (E) and
the relative amounts of amplifiable template are related
the formula E(Ctref - Cts). The amounts of template of each
test sample were then accordingly diluted.
Sensitivity determination of sequencing and HRM
Dilutions of the KRAS mutant HCT116 cell line (20%,
10%, 5% and 1%) were used to assess the relative sensitiv-
ity of DNA sequencing and HRM. The sensitivity testing
was performed with primers and conditions for the 189
bp KRAS product as above. Sequencing reactions for each
DNA dilution were performed using the Big Dye Termina-
tor v3.1 (Applied Biosystems, Foster City, CA) and the
results were analysed using Sequencher 4.6 (Gene Codes
Corporation, Ann Arbor, MI).
Detection of low levels of mutation by LCN-HRM in 
reconstruction experiments
The KRAS and EGFR mutant cell lines, HCT116 and NCI-
H1650, were used to show that LCN-HRM can detect low
levels of different types of mutations (missense mutations
and deletions respectively) and also to show that the
mutations can be characterised by subsequent sequencing
of individual LCN-HRM positive reactions.
Each cell line DNA was initially diluted at 5% mutant
allele frequency by mixing with normal peripheral blood
DNA based on qPCR data. The 5% cell line DNA mixtures
were then further diluted to an estimate of average four
copies in a one microlitre volume. Both cell line DNA
dilutions were tested by LCN-HRM in 65 replicates with
known positive and negative controls.
Quantitation of low-levels of mutant alleles by LCN-HRM
The frequency of a mutant allele may be estimated by
analysis of LCN-HRM reactions. The frequency of LCN-
HRM positive reactions approximates the amount of
mutant alleles present in the sample when the mutation
frequency is low.
For example, if 25 out of 72 LCN-HRM reactions (which
were tested with an average of four copies per reaction)
were scored as positive by melting curve analysis, the esti-
mated frequency of the mutant allele would be 8.7% {25/
(72 × 4)}. As the frequency of the mutant allele increases
or the average copy number per reaction increases, this
formula will become less accurate due to the possibility of
two mutant sequences being found in one reaction.
LCN-HRM of FFPE samples
DNA was previously extracted from four selected NSCLC
samples (TX13, TX49, TX86 and TX450) [15]. The first
three samples were positive for EGFR mutations by HRM
but not sequencing and the last sample was positive for
KRAS mutation by HRM but not sequencing. We tested
those samples by LCN-HRM to review the discrepancies
between HRM and the sequencing results. KRAS exon 2
LCN-HRM conditions were as above. TX13 was tested for
mutations in EGFR exon 19 (250 bp product), and TX49
and TX86 were screened for mutations in EGFR exon 21
(212 bp product). EGFR LCN-HRM assays were carried
out as previously described for HRM assays [14] except
that 65 cycles of amplification were performed. All sam-
ples were tested in 64 replicates using an estimated three
to four templates per LCN-HRM reaction except TX13
which was tested with less template (estimated 1 template
per reaction) due to the limited template available.
Fr number of tubes with positive reations total number o ={/ (              f f tubes average copy number      × )}Molecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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Positive reactions showing aberrant melting profiles were
selected and individually sequenced to verify the LCN-
HRM results. The selected LCN-HRM products were
directly column-purified using the PCR-M clean up kit
(Viogene, Taipei, Taiwan) and were eluted in a final vol-
ume of 30 μl.
LCN-HRM using DNA polymerases with proofreading 
activity
Two different reagent kits with proofreading activity were
assessed for their ability to accurately detect mutations:
the FastStart High Fidelity PCR System (Roche) and Hot-
Star HiFidelity polymerase (Qiagen). The fidelity was
reported to be approximately four-fold (FastStart High
Fidelity System) and ten-fold (HotStar HiFidelity) higher
than HotStarTaq DNA polymerase (Qiagen). TX84 DNA
was tested using LCN-HRM for EGFR exon 21 using the
two kits. LCN-HRM was performed on the Rotor-Gene Q
for both.
For the FastStart High Fidelity PCR System (Roche), the
reaction mixture in a final volume of 20 μl contained; 1×
PCR buffer, 2.5 mM MgCl2, 200 nM each primer, 200 μM
dNTPs, 5 μM SYTO 9, 1 U FastStart High Fidelity polymer-
ase. The cycling conditions were; one cycle of 95°C for 2
minutes; 60 cycles of 95°C for 10 seconds, 65°C for 10
seconds with an initial 10 cycles of touchdown (1°C/
cycle), 72°C for 30 seconds; one cycle of 97°C for one
minute and a melt from 70°C to 95°C rising 0.2°C per
second.
For HotStar HiFidelity enzyme (Qiagen), the reaction
mixture in a final volume of 20 μl contained; 1× PCR
buffer, 1.5 mM MgSO4, 200 nM each primer, 1.5 mM
dNTPs, 5 μM SYTO 9, 0.5 U HotStar HiFidelity polymer-
ase. The cycling conditions were; one cycle of 95°C for 5
minutes; 60 cycles of 95°C for 10 seconds, 67.5°C for 10
seconds with an initial 10 cycles of touchdown (1°C/
cycle), 72°C for 60 seconds; one cycle of 97°C for one
minute and a melt from 70°C to 95°C rising 0.2°C per
second. All conditions were tested in 64 replicates.
Results
The sensitivity of mutation detection by sequencing and 
HRM
The relative sensitivity of mutation detection by dideoxy-
nucleotide sequencing and HRM was compared using
dilutions of HCT116 DNA (heterozygous for the c.38G>A
KRAS mutation) in normal DNA. To ensure the maximum
accuracy in the sensitivity determination, qPCR of the
KRAS amplicon was used to estimate the effective concen-
tration of each DNA sample. The HCT116 cell line DNA
was then serially diluted into normal DNA at ratios of
40%, 20%, 10% and 2% to give mutant allele frequencies
of 20%, 10%, 5% and 1%.
Dideoxynucleotide sequencing and HRM were performed
at each of the mutant allele frequencies (Figure 1). The
mutant A allele was still detectable (at a low peak height)
when the mutant allele frequency was 20%. However,
when the mutant allele was present at 10%, it was only
distinguishable from the sequencing background because
the site of mutation was known. When the frequency of
the mutant was below 10%, the mutation was not detect-
able by dideoxynucleotide sequencing. Using HRM, the
5% dilution was readily detectable. The 1% dilution was
not distinguishable from the normal DNA controls.
Detection of low levels of mutation by LCN-HRM
HCT116 and NCI-H1650 DNA dilutions with a 5%
mutant allele frequency were sequencing negative for
KRAS exon 2 missense and EGFR exon 19 deletion muta-
tions respectively (Figure 1, data not shown for EGFR
exon 19). The same DNA mixtures were tested by LCN-
HRM with an estimate of average of three copies of tem-
plate per reaction. Melting curve analysis of LCN-HRM
amplicons led to the identification of positive reactions
which were expected to contain mutant alleles. 8/58 LCN-
HRM reactions of the 5% HCT116 DNA mixture and 12/
59 reactions of the 5% NCI-H1650 DNA mixture showed
aberrant melting. Subsequent sequencing of those posi-
tive reactions clearly showed the presence of the c.38G>A
KRAS  mutation and delE746_A750 EGFR  mutation
respectively (Figure 2).
The possible causes of discrepant results between 
sequencing and HRM
Four NSCLC samples extracted from FFPE tissues were
tested by LCN-HRM to investigate the cause of discrepant
results between HRM and sequencing. TX450 was nega-
tive by sequencing but positive by HRM for KRAS exon 2
[15]. After LCN-HRM which was performed with esti-
mated averages of four and seven copies per reaction, the
melting pattern of each individual reaction was analysed.
A total of 18/64 and 30/64 LCN-HRM reactions, display-
ing heteroduplex melting patterns or a shift of Tm were
scored as positive with four and seven copies respectively.
The frequency of mutant alleles was estimated to be 7%
with four copies {18 LCN-HRM positives/(64 × 4)} and
6.7% with seven copies {30 LCN-HRM positive/(64 × 7)}.
The same KRAS mutation, c.34G>T (p.G12C), was repeat-
edly detected when individual LCN-HRM positive reac-
tions (9 from the reactions with four copies and 10 from
the reactions with seven copies) were sequenced (Figure
3). Even though, the mutant allele was detectable in reac-
tions with both four and seven copies, it was predictably
more readily detectable with four copies, resulting in reli-
able characterisation of mutation by sequencing of multi-
ple LCN-HRM positive reactions.Molecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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Non-identical KRAS sequence variants were also detected
in five of the other LCN-HRM reactions; c.22G>A,
c.32C>A, c.38G>A, c.59C>T and c.100C>T. These transi-
tional changes have not been previously reported, except
those at positions 32 and 38. A transitional C>T change,
as opposed to a tranversional C>A, has been reported at
c.32 in a few cases whereas G>A change at c.38 (codon 13)
has been frequently reported. This illustrates the potential
dangers of working from just one sequence in a digital or
low copy number situation.
Three other FFPE samples from NSCLC patients were also
investigated by LCN-HRM for mutations in EGFR exons
19 (TX13) and 21 (TX49, TX86). After sequencing the
LCM-HRM positive products, multiple non-identical
sequence variants at different positions were detected in
all three samples. Those sequence variants are highly
likely to be artefacts. A total of 5 different EGFR sequence
variants, four exonic and one intronic, were found in
TX13 (Figure 4). All of the variants were single base sub-
stitutions with predominantly transitional changes (4/5).
Among these, two different sequence variations
(c.2192G>A and c.2224G>A) were found in one ampli-
con (reaction 24). Similarly, a total of 12 and 7 sequence
variants, again predominantly transitional changes, were
identified in TX49 (Table 1) and TX86 respectively (Table
2). Interestingly, a c.2488G>A change was found in two
independent amplicons of TX49. This mutation has not
been previously reported. This is difficult to interpret as it
may either represent a low level mutation in a background
of sequencing artefacts or a high probability sequencing
artefact.
LCN-HRM using DNA polymerases with proofreading 
activity
As the LCN-HRM assays were carried out with a Taq DNA
polymerase lacking proofreading activity, we investigated
whether the PCR artefacts were caused by polymerase
error or chemical damage to the FFPE DNA by using two
DNA polymerases having different levels of fidelity. We
hypothesised that if PCR artefacts were entirely DNA
polymerase mediated, the frequency of PCR artefacts
would decrease as the polymerase fidelity increased. The
fidelity of the polymerases were reported to be approxi-
mately four-fold (FastStart High Fidelity System, Roche)
and ten-fold (HotStar HiFidelity, Qiagen) higher com-
pared to the Taq polymerase.
One DNA sample (TX86) was tested with all three
polymerases. When the Taq  polymerase lacking proof-
reading activity (HotStar Taq) was used, nine out of 58
reactions (15.5%) were positive by LCN-HRM. A similar
LCN-HRM positive rate was detected with the FastStart
High Fidelity enzyme. Five out of 32 reactions (15.6%)
were positive. Surprisingly, the highest LCN-HRM posi-
tive rate was found with the HotStar HiFidelity enzyme.
Comparison of the mutation detection sensitivity of high resolution melting (HRM) and sequencing Figure 1
Comparison of the mutation detection sensitivity of high resolution melting (HRM) and sequencing. The sensi-
tivity of KRAS HRM and dideoxynucleotide sequencing was tested using four HCT116 DNA dilutions. Based on qPCR data, the 
HCT116 DNA was mixed with wild-type DNA to dilute the mutant allele to 20%, 10%, 5%, and 1% of the total alleles. 
Sequencing was only sensitive to 10-20% whereas HRM readily detected 5% mutant sequence. Panel A: Sequencing traces of 
four HCT116 DNA dilutions. The mutant A allele was readily detectable at a 20% mutant frequency. However, when the 
mutant allele was present at 10%, it was barely distinguishable from the sequencing background. When the frequency of the 
mutant was below 10%, the mutation was not detectable by dideoxynucleotide sequencing. Panel B: Using HRM, the mutation 
was readily detectable down at 5% mutation frequency. The 1% dilution was not distinct from the normal DNA. The melting 
curves of each dilution are shown in orange (20%), brown (10%), green (5%), red (1%) and blue (wild-type control).Molecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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Twenty-eight of 53 (52.8%) reactions were positive by
LCN-HRM (Table 3).
Numerous non-identical sequence variants were detected
in the sequencing of those 42 LCN-HRM positive reac-
tions (Table 2). The sequence variants were likely to be
PCR artefacts and the frequency of PCR artefacts was not
reduced with DNA polymerases having different levels of
proofreading activity, indicating that the artefacts were
principally due to damaged template.
Discussion
Overcoming the limits of detection of sequencing by LCN-
HRM
Molecular diagnostic testing of clinical tumour samples,
in which the tumour cells may comprise a small part of
the cellular material and where the quantity of sample for
analysis is limited, necessitates the use of highly sensitive
methods which are performable with low levels of tem-
plate. The gold standard method has been sequencing but
newer more sensitive methods often give results which
cannot be validated by the less sensitive conventional
sequencing methodology.
We developed a new screening method, LCN-HRM, for
the sensitive detection of sequence variation. LCN-HRM
uses limiting dilution of the DNA template for stochastic
mutant allele enrichment [20] followed by HRM for rapid
screening. The dilutions used are chosen such that muta-
tions if present can be detected well within the analytic
sensitivity of both HRM and conventional sequencing.
Thus any sequence variant present in aberrant melts can
be readily identified as the HRM products may be directly
sequenced.
The amount of starting template can affect the efficiency
of LCN-HRM due to the masking effect of wild-type allele,
when it is present at too high levels. On the contrary, the
use of suboptimal amounts of template increases the rate
of non-informative reactions giving no amplification.
Detection of low levels of mutations by LCN-HRM and characterisation by subsequent sequencing Figure 2
Detection of low levels of mutations by LCN-HRM and characterisation by subsequent sequencing. HCT116 and 
NCI-H1650 cell line DNA were mixed with normal DNA to a 5% mutant allele frequency based on the previous qPCR data. 
Each of the DNA mixtures were then tested by LCN-HRM in 65 replicates. An estimated average of three copies per reaction 
were added into the individual reaction. LCN-HRM using the diluted 5% HCT116 and 5% NCI-H1650 was performed for KRAS 
exon 2 and EGFR exon 19 respectively. LCN-HRM positive reactions, which were detected by melting curve analysis, were 
directly sequenced. The first derivative melting plots and sequencing traces of two of the representative LCN-HRM positive 
reactions are shown. (Panel A for 5% HCT116 and Panel B for 5% NCI-H1650). The identical KRAS mutation to the HCT116, 
c.38G>A, was detected by sequencing of reactions 62 and 72, which displayed aberrant melting pattern compared with wild 
type. The EGFR delE746_A750 was detected heterozygously in reaction 66 and a homozygously in reaction 30 by sequencing.Molecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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Using Ct values to estimate the effective number of tem-
plate molecules allows for the ready choice of an optimal
dilution to approximately four copies.
LCN-HRM for the detection of low level mutations in 
clinical samples
LCN-HRM was used to investigate the possible cause of
discordant results between HRM and sequencing. In our
previous HRM study of EGFR  and KRAS  mutations in
FFPE clinical samples, we observed that the number of
HRM positive samples were higher than sequencing posi-
tive samples [15]. In this study, we tested selected samples
from that study with LCN-HRM to investigate the appar-
ent discrepant results between sequencing and HRM.
One sample, TX450, was selected for LCN-HRM analysis
because although it was sequencing negative for a KRAS
exon 2 mutation, HRM showed similar aberrant melting
in replicates indicating the presence of a mutation. The
sample had an estimated 20% tumour content at histolog-
ical review. The detection of the identical KRAS mutation
(c.34G>T, p.G12C) in 19 multiple independent LCN-
HRM replicates proves that the discordant results origi-
nated from the different sensitivity of the two methods.
Frequent occurrence of artefacts in FFPE DNA samples
Another possible cause of discrepancy between HRM and
sequencing is due to PCR artefacts as various non-identi-
cal sequence variations were identified in the other three
FFPE samples tested. Artificial sequence changes are
reportedly mediated by DNA polymerase error and/or
damaged DNA templates [22,23]. A variety of DNA
polymerase-mediated sequence changes can occur during
PCR amplification including single base substitutions,
deletions and insertions. Among these changes, single
base substitutions result from misincorporation of incor-
rect dNTPs and are the most common type of artefactual
change. DNA damage induced during tissue fixation and
Detection of a KRAS mutations by LCN-HRM in a sequencing  negative clinical sample Figure 3
Detection of a KRAS mutations by LCN-HRM in a 
sequencing negative clinical sample. Testing of a clinical 
non-small cell lung cancer sample, TX450, for KRAS exon 2 
by sequencing gave a negative result whereas the sample was 
positive by HRM. LCN-HRM was thus performed in 64 repli-
cates using an estimate of average four copies per reaction. 
The difference graph plot and sequencing traces of three rep-
resentatives of LCN-HRM positive reactions are shown. A 
KRAS c.34G>T was detected in all three reactions by subse-
quent sequencing.
Table 1: Sequence variants detected in a NSCLC FFPE sample, TX49, by LCN-HRM.
Sample Position Base change Amino acid change Reported
TX49 c.2488 G>A p.D830N No
c.2488 G>A p.D830N No
c.2499 G>A p.L833L No
c.2502 G>A p.V834V No
c.2506 C>T p.R836C Yes
c.2507 G>T p.R836L No
c.2519 C>T p.A840V No
c.2526 C>T p.N842N No
c.2577 C>T p.A859A No
c.2581 C>T p.L861L No
c.2593 G>A p.E865K Yes
c.2603 A>G p.E868G Yes
c.2625+1 G>A - NoMolecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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storage process is another well-documented source of PCR
artefacts [23]. These PCR artefacts are randomly distrib-
uted and thus are masked by the abundant normal
sequences if high amounts of starting template are used.
In HRM analysis, a higher frequency of aberrant melting
is observed with FFPE DNA compared to high quality
DNA sample as the individual random PCR artefacts are
cumulatively reflected on the resulting melting curve
(results not shown).
Determining the origin of PCR artefacts
To understand whether the fidelity of DNA polymerase is
associated with the generation of PCR artefacts, we used
three DNA polymerase kits possessing different levels of
proofreading activity. The frequency of LCN-HRM posi-
tive reactions was compared in the EGFR exon 21 assay
using a FFPE sample, TX86, which had previously shown
aberrant HRM melting profiles. The rate of PCR artefacts
(which were confirmed by sequencing) was not reduced
as the fidelity of DNA polymerase was increased (Table 2).
Thus, the damaged DNA template is likely to be the prin-
cipal cause of PCR artefacts. In support of this, when a
peripheral blood DNA was tested by LCN-HRM using the
same conditions for KRAS exon 2, no amplicons showing
aberrant melting were detected (data not shown).
It is interesting that a higher LCN-HRM positive rate is
seen in LCN-HRM performed with the DNA polymerase
kit having the highest proofreading activity. This may be
explained by considering that mutation-prone transle-
sional extension at damaged DNA sites occurred more fre-
quently, resulting in subsequent generation of more
artefactual changes. The occurrence of translesional syn-
thesis at abasic sites has been previously reported with a
Taq polymerase with proofreading activity [24].
It is important to distinguish PCR artefacts from true
mutations in the results obtained from FFPE material by
LCN-HRM. The detection of an identical nucleotide
change at one position in over two or more independent
Table 2: The sequence variants detected in TX86 by LCN-HRM using three different DNA polymerases.
Polymerase Position Base change Amino acid change Reported
HotStarTaq
(Qiagen)
c.2515 G>T p.A839S No
c.2519 C>T p.A840V No
c.2527 G>A p.V842I Yes
c.2532 G>A p.L844L No
c.2583 G>A p.L861L No
c.2588 G>A p.G863D Yes
c.2592 G>A p.A864A No
FastStart High Fidelity
(Roche)
c.2602 G>A p.E868K No
c.2494 C>T p.R832C No
c.2512 C>T p.L838L No
c.2570 G>T p.G857V No
c.2576 C>T p.A859V No
HotStar HiFidelity
(Qiagen)
c.2478 C>A p.N826K No
c.2484 G>T p.L828F No
c.2488 G>T p.D830Y No
c.2492 G>A p.R831H Yes
c.2494 C>T p.R832C No
c.2508 C>A p.R836R SNP
c.2508_2509 CG>TA p.R836R, p.D837N No
c.2509 G>T p.D837Y No
c.2515 G>A p.A839T Yes
c.2517 A>G p.A839A No
c.2522 G>T p.R841M No
c.2530 C>A p.L844M No
c.2543 C>A p.P848Q No
c.2581 C>A p.L861M No
c.2591 C>T p.A864V No
c.2607 C>A p.Y869X No
c.2622 C>A p.G874G NoMolecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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PCR products is supportive of a true mutation whereas
nonidentical changes randomly distributed in the tem-
plate sequence should be considered as PCR artefacts. In
addition, weight should be given to those mutations that
are observed at well known (canonical) sites of mutation
over those mutations that occur at non-canonical sites.
Using these criteria, the identical KRAS  mutation
(c.34G>T) detected in multiple independent LCN-HRM
products amplified from the TX450 can be considered as
a true mutation. However, any variations that fail to be
confirmed would be more appropriately interpreted as
PCR artefacts as seen in TX13, TX49 and TX86 (Tables 1
and 2, Figure 4).
Fixation of tissue specimens in neutral buffered formalin
(10%) is a widely used preservation method as it helps to
maintain morphological features [23]. The adverse effect
of formalin on DNA quality results in fragmentation of
DNA into small sizes [25]. In addition, the incidence of
PCR artefacts has increased the risk of misinterpretation of
results obtained from formalin-fixed tissues [26,27]. Fur-
thermore, studies of chemical reactions between formal-
dehyde and DNA have demonstrated several chemical
interactions; formation of hydroxymethyl groups and
methylene bridges, generation of apurinic and apyri-
midinic sites, and hydrolysis of phosphodiester bonds
[28,29]. As a result, more frequent DNA polymerase errors
have been detected on FFPE material than fresh frozen tis-
sues [26,30].
Although the exact mechanism for the artefacts has not
been elucidated, several explanations are possible. Firstly,
adenosine residues tend to be incorporated complemen-
tary to damaged or cross-linked cytosine nucleotides, due
to the so-called "A-rule", generating G to A (or C to T)
mutations [26,31]. In this study, nearly all the base
changes were G to A or C to T mutations (Tables 1 and 2).
In addition, when Taq polymerase encounters damaged
templates, it has a propensity to stop nucleotide incorpo-
ration and to insert an non-complementary adenosine
residue into the strand being synthesised. The formalin-
induced DNA damage promotes jumping of the extending
primer to another template where extension of the primer
continues [32].
As FFPE tissue is frequently used for genetic analysis, the
results should thus always be cautiously interpreted. Tsao
et al. reported an incidence of 45 EGFR mutations in 177
NSCLC patients, comprising 13 deletions and 32 point
mutations [33]. However, due to the high frequency (53
percent) of novel variants with predominantly transition
changes (92 percent) in this study as well as the lack of
adequate confirmation, those changes were suggested to
be PCR artefacts [34,35], which is consistent with our
observations.
PCR artefacts detected in in a clinical FFPE sample (TX13) Figure 4
PCR artefacts detected in in a clinical FFPE sample 
(TX13). A total of 8 out of 31 LCN-HRM reactions were 
positive by melting curve analysis. Five non-identical 
sequence variants were detected from 4 of the 8 LCN-HRM 
positive reactions sequenced. In reaction 24, two transitional 
G>A changes were detected at positions c.2192 and c.2224. 
Two other exonic (c.2252C>T and c.2271G>T) and one 
intronic (c.2185-23T>C) variants were also detected in reac-
tions 45, 57 and 25 respectively.
Table 3: The frequency of LCN-HRM positives measured with different DNA polymerases in a NSCLC FFPE sample, TX86.
LCN-HRM HotStarTaq
(Qiagen)
FastStart High Fidelity
System (Roche)
HotStar HiFidelity
Polymerase (Qiagen)
Proofreading* 0 4-fold 10-fold
Positive 9 (15.5%) 5 (15.6%) 28 (52.8%)
Negative 49 (84.5%) 27 (84.4%) 25 (47.2%)
Total 58 (100%) 32 (100%) 53 (100%)
* Proofreading activity was relatively compared to that of a Taq DNA polymerase. HRM: high resolution melting.Molecular Cancer 2009, 8:82 http://www.molecular-cancer.com/content/8/1/82
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Recently, a large number of non-canonical EGFR muta-
tions were reported in both the stromal and epithelial tis-
sue in breast cancer [36]. The same group also reported
the occurrence of TP53 mutations in both the stromal and
epithelial tissue in breast cancer [37]. However, in an
independent study, no TP53 mutations were detected in
stroma of 17 breast cancer or breast cancer-associated
fibroblast cultures [38]. The vast majority of the "muta-
tions" reported are thus likely to be the same type of PCR
artefacts that we have observed in several of our samples
especially as the variants occurred at non-canonical sites
and were not adequately confirmed by sequencing of
independent PCR products. Consistent with this, the pre-
dominant change seen in the samples was a transitional
G>A (C>T) change [39,40].
In many cases, mutation analysis of FFPE samples in rou-
tine diagnostic situations involves low copy numbers
being amplified due to the combination of limited
amounts of template and degradation of DNA. Thus, a
low copy number may arise inadvertently. Such cases are
usually marked by late amplification and often by hetero-
geneity of melting patterns between samples. Interpreta-
tion is similar to that above. Sequencing is necessary to
interpret the results and the presence of a mutational
change must be confirmed using sequencing of independ-
ent reactions. In some cases, further dilution may be war-
ranted to optimise the copy number being analysed.
In conclusion, we have developed a new screening
method, LCN-HRM, for detection of low levels of
sequence variation. Analysis of multiple replicates of low
copy numbers of template allows both the detection of
templates with variant sequence (mutations) and enables
sequencing to identify the precise changes involved.
The previously reported discrepant results between HRM
and sequencing are often due to low level mutant alleles
but artefacts due to amplification of low copy numbers or
to damaged DNA from FFPE tissues must also be consid-
ered. The interpretation of LCN-HRM results should thus
be based on the reproducibility and position of detected
sequence changes.
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